[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Jazz Pharma Plc (JAZZ)

Jazz Pharma Plc (JAZZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,737,270
  • Shares Outstanding, K 62,739
  • Annual Sales, $ 4,268 M
  • Annual Income, $ -356,150 K
  • EBIT $ 224 M
  • EBITDA $ 921 M
  • 60-Month Beta 0.23
  • Price/Sales 2.94
  • Price/Cash Flow 12.29
  • Price/Book 2.81

Options Overview Details

View History
  • Implied Volatility 36.37% (-1.60%)
  • Historical Volatility 26.84%
  • IV Percentile 37%
  • IV Rank 24.11%
  • IV High 69.53% on 08/05/25
  • IV Low 25.84% on 11/24/25
  • Expected Move (DTE 14) 13.13 (6.48%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 119
  • Volume Avg (30-Day) 279
  • Put/Call OI Ratio 0.49
  • Today's Open Interest 8,782
  • Open Int (30-Day) 8,024
  • Expected Range 189.38 to 215.64

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $3.98
  • Number of Estimates 5
  • High Estimate $4.62
  • Low Estimate $3.14
  • Prior Year $0.60
  • Growth Rate Est. (year over year) +563.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
184.18 +10.06%
on 04/06/26
207.48 -2.30%
on 04/20/26
+14.43 (+7.66%)
since 04/01/26
3-Month
161.38 +25.60%
on 02/11/26
207.48 -2.30%
on 04/20/26
+38.21 (+23.23%)
since 01/30/26
52-Week
97.50 +107.90%
on 05/08/25
207.48 -2.30%
on 04/20/26
+85.52 (+72.98%)
since 05/01/25

Most Recent Stories

More News
Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA

Prescription Drug User Fee Act (PDUFA) date set for August 25, 2026

JAZZ : 202.72 (-0.15%)
Unpacking Q4 Earnings: Jazz Pharmaceuticals (NASDAQ:JAZZ) In The Context Of Other Pharmaceuticals Stocks

Unpacking Q4 Earnings: Jazz Pharmaceuticals (NASDAQ:JAZZ) In The Context Of Other Pharmaceuticals Stocks

JAZZ : 202.72 (-0.15%)
3 Overrated Stocks with Warning Signs

3 Overrated Stocks with Warning Signs

CALY : 15.22 (-0.52%)
JAZZ : 202.72 (-0.15%)
BAND : 44.24 (+20.18%)
Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026

DUBLIN , April 21, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its 2026 first quarter financial results on Tuesday, May 5, 2026, after the close of...

JAZZ : 202.72 (-0.15%)
Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin)

Rapid oral presentation of PD-L1 subgroup data from HERIZON-GEA-01 evaluating zanidatamab combinations, and additional analyses of tolerability, biomarker response and real-world treatment patterns in...

JAZZ : 202.72 (-0.15%)
Jazz Pharmaceuticals Stock, a Barchart Favorite, Trends Higher as Trump Renews Cannabis Hopes. Should You Buy JAZZ Here?

Jazz Pharmaceuticals stock pops as President Trump signals renewed urgency to reclassify cannabis as Schedule III drug. Technicals signal further upside ahead in JAZZ shares.

JAZZ : 202.72 (-0.15%)
3 Reasons to Sell JAZZ and 1 Stock to Buy Instead

3 Reasons to Sell JAZZ and 1 Stock to Buy Instead

JAZZ : 202.72 (-0.15%)
Save This Psychedelic Stock Watchlist After Trump’s Latest Executive Order

From manufacturers to high volatility biotechs, these are the mind-bending med stocks our Senior Market Strategist is watching now.

CMPS : 9.06 (+0.06%)
PSIL : 20.07 (-0.62%)
ATAI : 4.14 (-0.48%)
JAZZ : 202.72 (-0.15%)
PBM : 6.19 (-6.07%)
Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual Meeting

Six abstracts, including one oral presentation, underscore Jazz's ongoing commitment to generating real- world evidence addressing rare neurological disorders, including rare and severe forms...

JAZZ : 202.72 (-0.15%)
Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference

DUBLIN , April 1, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 25 th Annual Needham Healthcare Conference. Company management...

JAZZ : 202.72 (-0.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience & oncology. It derives the majority of its revenues from its sleep disorder drugs' Xywav & Xyrem. Both drugs are approved for treating cataplexy & excessive daytime sleepiness in narcolepsy patients....

See More

Key Turning Points

3rd Resistance Point 207.33
2nd Resistance Point 205.67
1st Resistance Point 204.34
Last Price 202.72
1st Support Level 201.35
2nd Support Level 199.69
3rd Support Level 198.36

See More

52-Week High 207.48
Last Price 202.72
Fibonacci 61.8% 165.47
Fibonacci 50% 152.49
Fibonacci 38.2% 139.51
52-Week Low 97.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.